Ataraxis AI Launches New AI Breast Cancer Test

Ataraxis Breast NEO predicts response to neoadjuvant therapy for breast cancer patients.

Apr. 9, 2026 at 3:26pm

Got story updates? Submit your updates here. ›

A translucent X-ray-style image revealing the internal structures of a human breast, with faint outlines highlighting tumor formations, conveying the clinical and investigative nature of a new AI-powered breast cancer diagnostic tool.A new AI-powered diagnostic test aims to help doctors better predict how breast cancer patients will respond to pre-surgical treatment.NYC Today

Ataraxis AI, a leading medical AI company, has launched a new diagnostic test called Ataraxis Breast NEO that uses artificial intelligence to predict how breast cancer patients will respond to neoadjuvant therapy. The test is designed to help doctors make more informed treatment decisions for their patients.

Why it matters

Neoadjuvant therapy, which involves administering cancer treatments before surgery, is an important part of care for many breast cancer patients. However, predicting which patients will respond well to this approach can be challenging. Ataraxis Breast NEO aims to provide doctors with valuable insights to guide their treatment recommendations and improve outcomes for patients.

The details

Ataraxis Breast NEO analyzes a patient's tumor sample using advanced AI algorithms to forecast their likely response to neoadjuvant therapy. This information can help doctors determine the most effective course of treatment for each individual. The test was developed using data from clinical studies and is intended to be used alongside other diagnostic tools in the breast cancer care pathway.

  • Ataraxis AI launched Ataraxis Breast NEO on April 9, 2026.

The players

Ataraxis AI

A leading medical AI company that develops diagnostic tests and tools to support cancer care.

Got photos? Submit your photos here. ›

What’s next

Ataraxis Breast NEO will be made available to healthcare providers in the coming months, allowing them to incorporate the test into their breast cancer treatment planning.

The takeaway

Ataraxis Breast NEO represents an important advancement in the use of AI to personalize and optimize breast cancer care, potentially leading to better outcomes for patients.